Year: 2025
Type: article
Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for developing both diagnostic and therapeutic tools for emerging diseases. Development of aptamers, nucleic acid-based ligands that bind to target molecules, has become an increasingly popular field in the context of drug discovery and diagnostics. Due to its simplicity, low-cost, and rapid synthesis, aptamer-based diagnostic tools have shown to be on par with antibody-based lateral flow assays and RT-qPCR, which make aptamers a potentially powerful and flexible tool to respond to future outbreaks. The SARS-CoV-2 viral surface receptor Spike protein is a prime candidate target for both diagnostic and therapeutic purposes. Through the process of systematic evolution of ligands by exponential enrichment (SELEX), receptor binding site (S-RBD)-specific aptamers were screened and developed over multiple cycles of SELEX. Amplified binding sequences from each round of selection were collected and assessed using Bio-layer interferometry (BLI), electrophoretic mobility shift assay (EMSA), and qualitative polymerase chain reaction (qPCR) melt curve analysis. The final mature heterogeneous aptamer pool (10R) was then purified and sequenced on the Illumina next generation sequencing (NGS) platform. Samples from intermediate heterogeneous pools showed increasing target affinity as selection cycles progressed, indicating affinity maturation as stronger binding aptamers were retained and amplified while the weaker sequences were removed from the selection pool. After identifying the top candidates with NGS, they were evaluated with BLI assay, and the best four sequences were assessed with capture aptamer linked immobilized sorbent assay (ALISA). Phophorothioate-modified aptamers were able to retain sequence integrity after 48 hours of incubation in near-physiological environment. However, the phosphorothioate-modified aptamers were not able to neutralize Spike-presenting lentiviral pseudovirus in a surrogate neutralization assay. In conclusion, the study evaluated the viability of aptamer development as a response to the Coronavirus disease 2019 (COVID-19) pandemic. Throughout the process of developing and characterizing SARS-CoV-2 S-RBD aptamer binders, the study identified the benefits and pitfalls of the approach, and suggested that the aptamer platform could be a powerful therapeutic and diagnostic tool for rapid pandemic response once the major challenges have been considered and addressed.
Source: Mspace (University of Manitoba)
Author: Chan, Rose
Institution: University of Manitoba
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funder: University of Memphis
OpenAlex ID: W7137664533
